Table 2.
Early-onset cataract | ||||||||
---|---|---|---|---|---|---|---|---|
No | Yes | |||||||
Event | PY | Rate# | Event | PY | Rate# | Crude HR*(95% CI) | Adjusted HR† (95% CI) | |
All | 194 | 40,186 | 4.83 | 73 | 9913 | 7.36 | 1.53 (1.17, 2.01)** | 1.32 (1.00, 1.73)* |
Gender | ||||||||
Women | 116 | 20,373 | 5.69 | 41 | 5043 | 8.13 | 1.43 (1.00, 2.05)* | 1.25 (0.87, 1.79) |
Men | 78 | 19,813 | 3.94 | 32 | 4869 | 6.57 | 1.68 (1.11, 2.53)* | 1.41 (0.93, 2.15) |
Stratify age | ||||||||
≤ 35 | 4 | 3872 | 1.03 | 8 | 966 | 8.28 | 7.97 (2.40, 26.5)*** | 6.04 (1.74, 21.0)** |
36–45 | 26 | 9493 | 2.74 | 16 | 2341 | 6.84 | 2.50 (1.34, 4.66)** | 2.46 (1.31, 4.61)** |
46–55 | 164 | 26,821 | 6.11 | 49 | 6606 | 7.42 | 1.22 (0.89, 1.68) | 1.09 (0.79, 1.50) |
Comorbidity‡ | ||||||||
No | 96 | 27,707 | 3.46 | 31 | 5476 | 5.66 | 1.63 (1.09, 2.44)* | 1.58 (1.05, 2.37)* |
Yes | 98 | 12,479 | 7.85 | 42 | 4436 | 9.47 | 1.21 (0.84, 1.73) | 1.20 (0.84, 1.73) |
Follow-up time‡ | ||||||||
≤ 4 years | 113 | 25,582 | 4.42 | 40 | 6404 | 6.25 | 1.42 (0.99, 2.03) | 1.13 (0.78, 1.63) |
> 4 years | 81 | 14,604 | 5.55 | 33 | 3509 | 9.40 | 1.70 (1.13, 2.54)* | 1.62 (1.08, 2.44)* |
Rate#, incidence rate, per 1000 person-years; Crude HR*, relative hazard ratio; Adjusted HR†: multivariable analysis including age, gender, and comorbidities of vertigo, insomnia, anxiety, and hearing loss; *p < 0.05, **p < 0.01, ***p < 0.001
Comorbidity‡: Patients with any one of the comorbidities vertigo, insomnia, anxiety, and hearing loss were classified as the comorbidity group
‡The follow-up time is partitioned into 2 segments (years ≤4, and > 4 years) by median